Fig. 5
UCHL3 is required for MS-BMDM-EXO-mediated BMSC osteogenesis in vitro. a, b qRT‒PCR of the mRNA expression of osteogenesis genes and Western blotting of RUNX2 and UCHL3 protein levels in BMSCs after treatment with UCHL3 inhibitor TCID, and DMSO as a control (n = 3). c Relative intensity analysis of b (n = 3). d, e ALP staining and Alizarin red staining in BMSCs after treatment with TCID, and DMSO as a control. Scale bar: 100 μm. f, g qRT‒PCR of the mRNA expression of Uchl3 and Western blotting of UCHL3 protein level in MS-BMDMs after treatment with siCon and siUchl3 (n = 3). h Western blotting of UCHL3 protein level in exosomes derived from MS-BMDMs after treatment with siCon and siUchl3. i, j qRT‒PCR of the mRNA expression of osteogenic genes and Western blotting of UCHL3 and RUNX2 protein levels in BMSCs after treatment with MS-BMDMssiCon-EXOs and MS-BMDMssiUchl3-EXOs. k Relative intensity analysis of j (n = 3). l, m ALP staining and Alizarin red staining in BMSCs after treatment with MS-BMDMssicon-EXOs and MS-BMDMssiUchl3-EXOs. Two-tailed unpaired Student’s t test was performed. **P < 0.01, ***P < 0.001; ns, not significant